Geneva, May 4 -- International Clinical Trials Registry received information related to the study (DRKS00040064) titled 'A Non-Interventional Study on the Tolerability, Safety and Effectiveness of Asciminib in newly diagnosed and pre-treated Ph+ CML in CP patients in Germany - the ASC2ADHERE study' on April 22.
Study Type: observational
Study Design:
Allocation:
Masking:
Control:
Assignment:
Study design purpose: treatment
Primary Sponsor: Novartis Pharma GmbH
Condition:
C92.1
Chronic myeloid leukaemia [CML], BCR/ABL-positive
Intervention:
Group 1: Asciminib cohort: Approximately 300 patients, including both newly diagnosed and pre-treated individuals. At least 50% of patients are expected to be treated in first-line. In case of s...